Aptar Pharma to support Aceso’s inhaled cystic fibrosis candidate’s advance

Aptar's ACT-101 is designed to intervene a step earlier than current CF modulators. Aptar's ACT-101 is designed to intervene a step earlier than current CF modulators. Aceso intends to make an IND filing with the FDA in 2027, teeing up clinical trials for ACT-101. Credit: Jo Panuwat D/Shutterstock.com Drug delivery specialist Aptar Pharma is collaborating with Aceso Therapeutics to advance development for the latter’s ACT-101 – an inhalable antisense oligonucleotide (ASO) designed to treat the underlying disease mechanisms of cystic fibrosis (CF). Under the pair-up, Nanopharm, Aptar’s specialist inhalation development services business, will lead formulation development and device assessment activities…

Source: Medical Device Network